SEC Filings
Xencor Picks Top Dose For Kidney Cancer Drug After 45.5% Response Rate In Small Cohort
The company plans FDA talks on an accelerated approval path and a head-to-head trial against tivozanib, with cash it expects to last into 2029.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The company plans FDA talks on an accelerated approval path and a head-to-head trial against tivozanib, with cash it expects to last into 2029.
SEC Filings
Jackson starts November 30, succeeding interim CFO Claude Russ, and gets $5 million in special stock to replace forfeited AutoZone awards.
Deals
The cell-therapy developer proposes 9,375,000 shares on Nasdaq under ASPE after a reverse stock split, with about $72.4 million in cash at June 30.
SEC Filings
AutoZone's controller will cover both top finance roles from November 25 while the company searches outside for a permanent CFO.
SEC Filings
A new technical report on Nolan Creek lists resources but no mineral reserves, mining methods, capital costs or economic analysis.
Earnings
The carrier cut device subsidies, widened its adjusted EBITDA margin to 40.2% and lifted its 2026 postpaid phone forecast to 1.1 million to 1.2 million.
SEC Filings
Vertiv bought a Dublin-area firm that flushes and load-tests liquid-cooled data centers; terms were not disclosed, the company said.
SEC Filings
Swan leaves effective November 11 to pursue other opportunities, and Atmus says the exit did not stem from any disagreement.
SEC Filings
The Indian travel platform's hotels, packages and bus segments grew adjusted margin by 20.2% and 29.0% in constant currency.
Deals
The Boston antibody developer proposes selling 9,375,000 shares while its cash fell to about $57.2 million at September 30.
Deals
Range holders would own about 27% of the combined company, and two Range directors would join EQT's board.
SEC Filings
A 541-patient late-stage trial showed a modest progression-free survival gain, with more lung disease than in earlier studies of the drug.